CA2378646A1 - Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies - Google Patents
Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies Download PDFInfo
- Publication number
- CA2378646A1 CA2378646A1 CA002378646A CA2378646A CA2378646A1 CA 2378646 A1 CA2378646 A1 CA 2378646A1 CA 002378646 A CA002378646 A CA 002378646A CA 2378646 A CA2378646 A CA 2378646A CA 2378646 A1 CA2378646 A1 CA 2378646A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- nhl
- bone marrow
- chimeric
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14828799P | 1999-08-11 | 1999-08-11 | |
US60/148,287 | 1999-08-11 | ||
PCT/US2000/040459 WO2001010462A1 (en) | 1999-08-11 | 2000-07-25 | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2378646A1 true CA2378646A1 (en) | 2001-02-15 |
Family
ID=22525101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002378646A Abandoned CA2378646A1 (en) | 1999-08-11 | 2000-07-25 | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1207906A4 (no) |
JP (1) | JP2003513012A (no) |
CN (2) | CN101259270A (no) |
AU (1) | AU784971B2 (no) |
CA (1) | CA2378646A1 (no) |
HK (1) | HK1048945A1 (no) |
MX (1) | MXPA02001398A (no) |
MY (1) | MY136635A (no) |
NO (1) | NO20020639L (no) |
TW (1) | TWI279233B (no) |
WO (1) | WO2001010462A1 (no) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU777970C (en) | 1999-05-07 | 2006-08-17 | F. Hoffman-La Roche Ag | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
PT3284753T (pt) | 2002-10-17 | 2020-05-04 | Genmab As | Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla |
EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
CA2519870A1 (en) | 2003-04-09 | 2004-10-28 | Genentech, Inc. | Use of rituximab intravenous compositions to treat rheumatoid arthritis |
JP5416338B2 (ja) | 2003-05-09 | 2014-02-12 | デューク ユニバーシティ | Cd20特異的抗体およびその使用方法 |
CA2526402A1 (en) | 2003-06-05 | 2005-01-20 | Genentech, Inc. | Blys antagonists and uses thereof |
DK2348051T3 (en) | 2003-11-05 | 2019-03-18 | Roche Glycart Ag | CD20 antibodies with increased fc receptor binding affinity and effector function |
JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー/エスGenmab A/S | Cd20に対するヒトモノクローナル抗体 |
CN106075435A (zh) | 2004-06-04 | 2016-11-09 | 健泰科生物技术公司 | 用于治疗多发性硬化的方法 |
BR122018016031B8 (pt) | 2004-08-04 | 2021-07-27 | Applied Molecular Evolution Inc | processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada |
WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
CN101267836A (zh) | 2005-07-25 | 2008-09-17 | 特鲁比昂药品公司 | 单剂量cd20特异性结合分子的用途 |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
US9726673B2 (en) | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
SG10202005450PA (en) | 2007-07-09 | 2020-07-29 | Genentech Inc | Prevention of disulfide bond reduction during recombinant production of polypeptides |
WO2009052293A1 (en) | 2007-10-16 | 2009-04-23 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
WO2010074724A1 (en) | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
RU2639288C2 (ru) | 2009-08-11 | 2017-12-20 | Дженентек, Инк. | Получение белков в культуральных средах без глутамина |
TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
EP2536279A4 (en) | 2010-02-19 | 2013-07-24 | Millennium Pharm Inc | CRYSTALLINE FORMS OF SODIUM 4 - {[9-CHLORO-7- (2-FLUORO-6-METHOXYPHENYL) -5H-PYRIMIDO [5,4-D] [2] BENZAZEPHIN-2YL] AMINO} -2-METHOXYBENZOATE |
US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
CN105209042B (zh) | 2013-03-22 | 2019-03-08 | 米伦纽姆医药公司 | 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合 |
EP3247395A1 (en) * | 2015-01-23 | 2017-11-29 | Immunomedics, Inc. | Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma |
EP3303373B1 (en) | 2015-05-30 | 2020-04-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
BR112017024610A2 (pt) | 2015-06-24 | 2018-07-31 | F. Hoffmann-La Roche Ag | anticorpos para receptor antitransferrina com afinidade especificada |
CN108367004B (zh) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | Cd3结合多肽 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CN114031689A (zh) | 2015-10-02 | 2022-02-11 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
MX2019003029A (es) * | 2016-09-16 | 2019-09-13 | Nordic Nanovector Asa | Tratamiento de linfoma no hodgkin usando lilotomab y 177lu-lilotomab satetraxetano. |
CN108421048B (zh) * | 2016-09-28 | 2021-04-20 | 首都医科大学附属北京世纪坛医院 | 纳米活性碳靶向药物递送系统、制备方法及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2091684T3 (es) * | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
EP1112084B2 (en) * | 1998-08-11 | 2012-04-25 | Biogen Idec Inc. | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
US6451284B1 (en) * | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
US8557244B1 (en) * | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
-
2000
- 2000-07-25 MX MXPA02001398A patent/MXPA02001398A/es active IP Right Grant
- 2000-07-25 CN CNA2008100921383A patent/CN101259270A/zh active Pending
- 2000-07-25 CN CNB008116644A patent/CN100389825C/zh not_active Expired - Lifetime
- 2000-07-25 JP JP2001514978A patent/JP2003513012A/ja active Pending
- 2000-07-25 CA CA002378646A patent/CA2378646A1/en not_active Abandoned
- 2000-07-25 WO PCT/US2000/040459 patent/WO2001010462A1/en active Application Filing
- 2000-07-25 EP EP00965561A patent/EP1207906A4/en not_active Withdrawn
- 2000-07-25 AU AU76260/00A patent/AU784971B2/en not_active Expired
- 2000-08-03 MY MYPI20003551A patent/MY136635A/en unknown
- 2000-08-10 TW TW089116114A patent/TWI279233B/zh not_active IP Right Cessation
-
2002
- 2002-02-08 NO NO20020639A patent/NO20020639L/no not_active Application Discontinuation
-
2003
- 2003-02-18 HK HK03101198.5A patent/HK1048945A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
TWI279233B (en) | 2007-04-21 |
JP2003513012A (ja) | 2003-04-08 |
CN1373671A (zh) | 2002-10-09 |
WO2001010462A1 (en) | 2001-02-15 |
CN101259270A (zh) | 2008-09-10 |
CN100389825C (zh) | 2008-05-28 |
EP1207906A4 (en) | 2005-07-06 |
MY136635A (en) | 2008-11-28 |
EP1207906A1 (en) | 2002-05-29 |
AU7626000A (en) | 2001-03-05 |
HK1048945A1 (en) | 2003-04-25 |
AU784971B2 (en) | 2006-08-10 |
NO20020639D0 (no) | 2002-02-08 |
NO20020639L (no) | 2002-04-11 |
MXPA02001398A (es) | 2002-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU784971B2 (en) | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies | |
US10400043B2 (en) | Treatment of diffuse large-cell lymphoma with anti-CD20 antibody | |
KR102595561B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
JP2019065023A (ja) | 抗cd20抗体の投与を含むb細胞リンパ腫の併用療法 | |
EP1131096B1 (en) | Anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants | |
CN110536905A (zh) | 用于治疗肺癌的抗pd-1抗体 | |
AU2017219596A1 (en) | Chimeric canine anti-CD20 antibody | |
KR20200010472A (ko) | 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임 | |
AU2005211669B2 (en) | Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody | |
TWI280137B (en) | Treatment of intermediate-and high-grade non-Hodgkins lymphoma with anti-CD20 antibody | |
EP2264070A1 (en) | Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-CD20 antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |